CategoryMedical & Pharma
APASL - Asian Pacific Association for the Study of the Liver
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to APASL - Asian Pacific Association for the Study of the Liver — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
APASL 2027 (APASL – Asian Pacific Association for the Study of the Liver)
Event Snapshot
- Official event: 36th Annual Meeting of APASL 2027
- Dates: 1 - 4 April 2027
- Venue: International Convention Centre
- City & Country: Sydney, Australia
- Conference theme: Transforming Liver Medicine: Innovation in Practice
- Key clinical/scientific focus areas (as stated): MAFLD, HBV, HCV, HCC, Basic and Translational Research, Endo Hepatology, Cholestatic Liver Disease, Portal Hypertension, DILI, and Transplant
- Expected delegates: more than 2,500 delegates
Why This Conference Matters (High-Level Context)
APASL 2027 is positioned as Asia-Pacific’s premier liver conference and represents a high-density scientific and clinical community centered on hepatology. With an expected turnout of more than 2,500 delegates and a strong international presence across Asia-Pacific, APASL 2027 brings together clinicians, researchers, academic leadership, healthcare institutions, and industry stakeholders focused on liver disease prevention, diagnosis, and treatment.
The scientific program theme—Transforming Liver Medicine: Innovation in Practice—signals a meeting built for translational science and real-world clinical implementation. For organizations active in hepatology therapeutics, liver diagnostics, translational research ecosystems, and clinical research partnerships, APASL is designed to create engagement around contemporary liver disease priorities such as MAFLD, viral hepatitis (HBV/HCV), liver cancer (HCC), cholestatic disease, portal hypertension, DILI, and transplant pathways.
1️⃣ Who Attends (Buyers / Attendees)
APASL is not just an abstract-driven scientific gathering; it is also an industry and collaboration platform where decision influencers and operational leaders congregate around hepatology innovation.
Main attendee groups
- Hepatologists and gastroenterologists (clinical decision-makers and evidence evaluators)
- Translational researchers and clinical scientists (basic-to-clinical pathway builders)
- Hospital specialists and department leadership (institution-level adoption of clinical programs)
- Researchers and academic faculty (study design, investigator networks, and institutional collaboration)
- Industry representatives aligned to liver therapeutics, diagnostics, and research tooling
- Clinical operations and medical affairs teams (protocol planning support, evidence generation coordination, scientific communications)
Buyer-fit perspective (who is most likely to engage)
We see the highest engagement potential among teams that connect evidence, clinical pathways, and adoption:
- Medical Affairs leadership for hepatology-focused portfolios
- Clinical Development and Clinical Operations stakeholders working on MAFLD/HBV/HCV/HCC and related indications
- Market Access / Health Economics stakeholders who shape adoption pathways
- Commercial leadership for gastroenterology/hepatology (regionally focused strategy)
- Institutional ecosystem buyers (hospitals/universities, liver centers) who evaluate research collaboration opportunities
2️⃣ Where the Show Is Happening + Attendee Geographic Origin
Location
APASL 2027 will be held in Sydney, Australia at the International Convention Centre.
Geographic origin of attendees
Based on the official description, the meeting is expected to have a strong international presence particularly from across Asia-Pacific. As an Australia-hosted APASL meeting, the event is also likely to pull additional delegates from Australia and the broader Oceania region.
In practical terms, the strongest targeting lens for outreach and engagement is:
- Asia-Pacific hubs (multi-country attendance patterns)
- Regional travel from Asia with clinician-researcher and institutional delegations
- Australia-based participation as a major local anchor
- Cross-border industry representation for hepatology programs with global/regional footprints
3️⃣ Audience Reach (Local / National / Global)
APASL 2027 is best characterized as regional-to-global rather than purely local or national.
- Core reach: Asia-Pacific
- Expected profile: cross-border scientific and industry collaboration
- Why global elements appear: the hepatology community and major liver-disease focus areas (HBV/HCV/HCC/MAFLD and more) attract international participants and industry stakeholders with multi-country programs
4️⃣ Sample Buyer Company Names (BUYERS ONLY) + Websites
Below are buyer-fit sample organizations that typically align with hepatology priorities, clinical research activity, and gastrointestinal/hepatology commercial and medical teams. These are provided as research starting points for the attendee and stakeholder ecosystem. If we have your client product website, we can refine the list to the closest matching buyer archetypes.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Gilead Sciences | https://www.gilead.com | Medical Director, Gastroenterology/Hepatology (HBV/HCV) / Medical Affairs Lead | Strong alignment with viral hepatitis and liver disease evidence communities; APASL’s HBV/HCV focus matches where Medical Affairs leaders are actively involved. |
| 2 | Roche (Genentech) | https://www.roche.com | Therapeutic Area Lead, Gastroenterology/Hepatology / Global Medical Affairs Director | APASL’s translational and clinical transformation theme suits global medical leadership engaged in liver cancer and hepatology innovation. |
| 3 | Bristol Myers Squibb (BMS) | https://www.bms.com | Senior Director, Clinical Development (GI/Hepatology) / Clinical Program Lead | HCC and end-stage liver disease focus areas commonly connect with oncology and translational hepatology pipelines. |
| 4 | AbbVie | https://www.abbvie.com | Vice President, Medical Affairs (GI/Hepatology) / TA Medical Lead | Commercial and medical strategy in immunology and GI-adjacent portfolios often intersects with liver disease treatment evolution and scientific sessions. |
| 5 | Merck & Co. (MSD) | https://www.merck.com | Director, Clinical Operations / Clinical Studies Lead (GI/Oncology) | APASL program topics like HCC and translational research create strong relevance for clinical operations leadership. |
| 6 | GSK | https://www.gsk.com | Medical Affairs Director, Gastroenterology / Hepatology Portfolio Lead | Scientific meetings like APASL attract global medical stakeholders who manage evidence and engagement plans. |
| 7 | Sanofi | https://www.sanofi.com | Head of Clinical Development (GI/Liver) / TA Clinical Lead | Liver disease innovation themes and MAFLD focus provide strong fit for clinical program leadership. |
| 8 | Takeda | https://www.takeda.com | Global Medical Affairs Lead, Hepatology / Scientific Engagement Manager | APASL’s broad liver-disease scope (HBV/HCV/MAFLD/HCC) aligns with hepatology medical engagement needs. |
| 9 | AstraZeneca | https://www.astrazeneca.com | Director, Clinical Trials (Liver/HCC) / Translational Medicine Program Manager | HCC and translational research emphasis matches where trial operations and translational program managers collaborate. |
| 10 | Abbott | https://www.abbott.com | Director, Medical Affairs (Diagnostics/GI) / Clinical Evidence Manager | If your solution supports diagnostics, specimen workflows, biomarkers, or clinical evidence, APASL’s clinical focus makes it a high-fit meeting. |
| 11 | Danaher (Beckman Coulter / Others) | https://www.danaher.com | Clinical Evidence Lead / Diagnostics Strategy Manager | Liver disease biomarker discovery and translational research communities create strong demand for lab and diagnostics evidence and partnerships. |
| 12 | Thermo Fisher Scientific | https://www.thermofisher.com | Strategic Account Manager, Clinical Research / Scientific Partnerships Manager | Basic and translational research tracks often drive demand for research tools, reagents, and lab platforms. |
| 13 | Amgen | https://www.amgen.com | Senior Director, Medical Affairs (GI/Oncology) / Clinical Strategy Lead | HCC and oncology adjacent liver research themes bring medical strategy teams to major scientific conferences. |
| 14 | Biogen | https://www.biogen.com | Director, Scientific Partnerships / Translational Research Collaboration Lead | Where translational pathways matter, partnership-driven organizations often target key hepatology scientific audiences. |
| 15 | Vertex Pharmaceuticals | https://www.vrtx.com | Medical Affairs Lead (Viral Hepatitis) / Clinical Program Manager | HBV/HCV disease focus is strongly aligned with organizations working on viral hepatitis transformation and evidence generation. |
| 16 | IQVIA (buyer-type: clinical research & analytics ecosystem) | https://www.iqvia.com | Healthcare Analytics Sales Director / Clinical Research Services Lead | APASL is a natural place for analytics, real-world evidence, and clinical research services stakeholders supporting hepatology programs. |
| 17 | CRO / Clinical Research Services Provider (example: ICON) | https://www.iconplc.com | Director, Clinical Operations / Therapeutic Area Program Lead (GI/Oncology) | With multiple liver indications and translational research, CRO program leads often seek study and investigator network engagement. |
| 18 | Medtronic (if workflow/technology enabled in care settings) | https://www.medtronic.com | Clinical Solutions Manager (Gastro/Liver Care) / Field Medical Technology Lead | If the offering supports clinical workflow, devices, or care delivery improvements connected to liver management, APASL’s portal hypertension/DILI/transplant conversations can create relevance. |
Top buyer-fit sample set to prioritize first (starter shortlist)
- Gilead Sciences
- Roche
- Bristol Myers Squibb
- AbbVie
- Merck
We can tighten this shortlist further based on your client’s exact product category (therapeutics vs. diagnostics vs. research tools vs. clinical workflow vs. compliance/training platform, etc.).
5️⃣ Job Profiles, Industries & Event Type
Best job profiles to target
- Medical Affairs Director / Medical Director (Gastroenterology, Hepatology, GI/Oncology)
- Clinical Development Director (liver disease indications, MAFLD, HBV/HCV, HCC)
- Clinical Operations Lead (trial management, site engagement, protocol execution)
- Translational Medicine / Basic Research Program Manager
- Scientific Partnerships Lead (academic collaboration, research alliances)
- Market Access / Health Economics & Outcomes Research (HEOR) Lead
- Country / Regional Business Lead (hepatology portfolio commercialization strategy)
- Diagnostics Clinical Evidence Manager (biomarkers, testing pathways)
- Scientific Communications / Publication Strategy Manager (education and evidence dissemination)
- Department/Center Program Leadership for liver centers and hospital research units
Industries to use (aligned to the provided industry list)
We recommend using the following industries as the first-pass targeting set (from your provided Apollo industry list):
- Pharmaceuticals
- Biotechnology
- Hospital & Health Care
- Medical Devices
- Research
- Medical Practice
- Information Technology & Services (only if the product is clinical software, evidence platforms, or digital care tooling)
- Market Research (only if the product is evidence generation, HCR analytics, or real-world evidence services)
- Professional Training & Coaching (only if the product is training/education for clinicians or patient pathways)
Event type (how to classify it)
- Medical & Scientific Conference
- Hepatology / Gastroenterology Congress
- Clinical Research & Translational Medicine Meeting
- Industry Collaboration Platform (medical affairs, clinical development, diagnostics/tools, and research services engagement)
6️⃣ Estimated Attendance (Expected Total Footfall)
The official event description indicates APASL 2027 is expected to welcome more than 2,500 delegates.
For planning and audience analysis, we treat this as a high-intensity multi-stakeholder conference where footfall is composed of:
- Scientific delegates (hepatology clinicians, researchers)
- Academic and clinical institution stakeholders
- Industry representatives aligned to liver disease priorities
- Poster/abstract contributors and session attendees
7️⃣ Key Focus Areas & Buyer Engagement
Key clinical/scientific focus areas (as stated)
- MAFLD
- HBV
- HCV
- HCC
- Basic and Translational Research
- Endo Hepatology
- Cholestatic Liver Disease
- Portal Hypertension
- DILI (Drug-Induced Liver Injury)
- Transplant
Where buyers are most likely to engage
Buyers and decision influencers generally cluster engagement around the intersection of evidence, clinical workflow, and translational outcomes:
- Medical Affairs engagement around evidence dissemination, scientific education, and clinical trial/community knowledge
- Clinical Development / Operations engagement around study feasibility, liver-center networks, protocol discussions, and translational alignment
- Research engagement around translational collaborations, biomarker research opportunities, and laboratory innovation
- Commercial engagement where regional strategy meets high-authority scientific audiences
- Diagnostics/lab ecosystem engagement where testing pathways and biomarker validation are discussed
Best engagement angles (what we would align messaging to)
- “Transforming liver medicine” narrative fit with innovation-in-practice
- Indication-specific relevance (MAFLD, HBV/HCV, HCC, etc.)
- Translational and implementation value (basic research to clinical application)
- Clinical collaboration readiness (partnerships with hospitals, liver centers, researchers)
- Evidence generation support (clinical evidence, outcomes measurement, research tooling)
8️⃣ Client Product Fit & Buyer Selection (Required Next Step)
We can tailor the “best buyer” list precisely to your client’s needs, but we need the client product review details and the client website. Please share the client website URL and (if available) the client’s product category (e.g., therapeutics, diagnostics, CRO/clinical services, research tools, clinical software, training content).
What we will do after receiving your client website
- Map your product to APASL’s stated liver disease priorities (MAFLD, HBV, HCV, HCC, DILI, transplant, etc.)
- Select buyer archetypes that most directly benefit from the product (Medical Affairs vs Clinical Development vs Diagnostics Evidence vs Research Partnerships)
- Recommend the best-matching industries from the provided list (Pharmaceuticals, Biotechnology, Medical Devices, Research, Hospital & Health Care, etc.)
- Produce a refined buyer shortlist in the format you requested (Priority, Company, Website, Best Title to Target, Why This is a Good Buyer Fit)
Buyer examples by product type (conditional guidance)
- If the product is therapeutics focused on viral hepatitis or liver cancer: we prioritize Medical Affairs and Clinical Development leadership targeting HBV/HCV/HCC tracks.
- If the product is MAFLD-focused: we prioritize clinical programs and translational evidence leaders, including HEOR/Market Access if adoption is a key goal.
- If the product is diagnostics/biomarkers: we prioritize Diagnostics Clinical Evidence managers and translational researchers working on testing pathways.
- If the product is research tools/lab platforms: we prioritize Translational Research and Scientific Partnerships leads.
- If the product is clinical software/workflow/evidence platforms: we prioritize clinical operations, HEOR analytics, and health information stakeholders (using IT services and market research industry filters appropriately).
9️⃣ Final Recommendation (How We Position APASL 2027 for Buyer Outreach)
APASL 2027 is a strong candidate for a focused buyer stakeholder program because it combines:
- High authority scientific programming in hepatology and liver medicine transformation
- Clear indication clusters (MAFLD, HBV/HCV, HCC, cholestatic disease, portal hypertension, DILI, transplant)
- Expected scale of more than 2,500 delegates with strong Asia-Pacific international presence
- Direct relevance to industry collaboration across medical affairs, clinical development, diagnostics, translational research, and healthcare institutions
Once we receive the client website, we will deliver an optimized buyer shortlist and a best-fit job-title targeting map aligned to the exact product use case and the APASL liver priorities.
Quick Reference Details (Extracted from Official Source)
- Dates: 1 April 2027 to 4 April 2027
- Venue: International Convention Centre
- City: Sydney
- Country: Australia
- Expected delegates: more than 2,500
Data sheet
APASL - Asian Pacific Association for the Study of the Liver – Event Attendee & Buyer Profile Analysis
Event Date: 1–4 April 2027
Location: Sydney, Australia
Event Status: Upcoming
Research Date: 30 June 2026
Event Overview
| Event Name | APASL 2027 |
| Event Date | 1–4 April 2027 |
| Event Status | Upcoming |
| Venue | International Convention Centre |
| City | Sydney |
| State / Region | New South Wales |
| Country | Australia |
| Organizer | Asia Pacific Society for the Study of the Liver (APASL) / APASL 2027 organizing committee with GESA support |
| Official Event Website | apasl2027.org |
| Event Type | International medical congress / scientific conference |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; Wellness, Health & Fitness |
| Audience Reach | Global with strongest concentration in Asia–Pacific |
| Estimated Attendance / Expected Footfall | Expected to welcome more than 2,500 delegates |
| Attendance Data Reliability | Confirmed by official event website; organizer states “more than 2,500 delegates” expected |
| Main Purpose of Event | Scientific exchange, clinical education, research updates, and industry collaboration focused on liver disease and hepatology |
About the Event
APASL 2027 is the 36th Annual Meeting of the Asian Pacific Association for the Study of the Liver and is positioned as a leading regional scientific congress for hepatology professionals. The official program emphasizes liver medicine innovation, clinical practice, translational research, and disease-specific themes including MAFLD, HBV, HCV, HCC, endo-hepatology, cholestatic liver disease, portal hypertension, DILI, and transplant.
This event matters because it brings together clinicians, researchers, academic institutions, healthcare organizations, and industry stakeholders involved in liver health. It is highly relevant for B2B lead generation in medical devices, diagnostics, pharmaceuticals, clinical research services, hospital procurement, and healthcare technology, particularly where decision-makers seek evidence-based solutions, research partnerships, and specialty care innovation.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Hepatology clinicians | Hospitals, liver centers, specialist practices, academic medical centers | Clinical evaluation, protocol adoption, referral influence | High-value audience for diagnostics, therapeutics, procedural tools, and care pathways |
| Hospital procurement and supply chain teams | Public and private hospitals, health systems, medical centers | Purchasing, vendor evaluation, contract management | Important for medical devices, lab equipment, consumables, and service contracts |
| Researchers and translational science leads | Universities, research institutes, biomed organizations | Study design, research purchasing, partnership selection | Relevant for assays, reagents, data platforms, CROs, and academic collaborations |
| Pharmaceutical and biotech medical teams | Drug manufacturers, biotech firms, medical affairs teams | Scientific engagement, evidence generation, KOL relations | Strong fit for therapies, trial recruitment, medical communications, and real-world evidence services |
| Diagnostics and laboratory leaders | Pathology labs, reference labs, diagnostic companies | Product selection, workflow evaluation, clinical adoption | Relevant for biomarker testing, imaging, molecular diagnostics, and lab automation |
| Academic society and association leaders | Professional societies, specialty associations, educational bodies | Program influence, sponsorship selection, partnership development | Useful for education platforms, sponsorships, and long-term relationship building |
| Clinical trial and CRO stakeholders | CROs, site networks, research service providers | Vendor selection, site identification, trial operations | Strong for patient recruitment, eClinical, data capture, and trial operations solutions |
| Government health stakeholders | Public health agencies, health departments, policy organizations | Guideline influence, procurement oversight, funding priorities | Relevant for population health, screening, prevention, and health system programs |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Sydney | Local hospitals, universities, medical groups, life science companies | Medium | Large metro with major healthcare and research ecosystem |
| Host state / region: New South Wales | Statewide hospitals, health networks, universities, pharma offices | High | Strong nearby buyer base for healthcare and research vendors |
| Nearby business hubs | Melbourne, Brisbane, Canberra, Adelaide | High | Draws domestic clinicians, procurement teams, and research partners |
| National reach | Australia-wide healthcare, academic, and industry attendees | High | Major national conference destination and travel hub |
| International reach | Asia–Pacific, Europe, North America, Middle East specialists and industry delegates | High | Official site notes a strong international presence, particularly from Asia–Pacific |
| Key trade corridors / regions | Australia–Asia medical research, pharma, diagnostics, and hospital procurement corridors | High | Particularly relevant for regional commercialization and KOL engagement |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | Official messaging describes APASL as a leading global meeting with strong international participation and a large Asia–Pacific footprint. |
4. Sample Buyer Companies and Websites
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Royal Prince Alfred Hospital | Hospital / clinical buyer | Major Sydney tertiary hospital; relevant for hepatology, procurement, and clinical research | slhd.nsw.gov.au | Director of Procurement, Clinical Director, Gastroenterology/Hepatology Head | Strong Market Fit, Attendance Not Confirmed |
| St Vincent’s Hospital Sydney | Hospital / clinical buyer | Large tertiary hospital with specialist services and research activity | svhs.org.au | Medical Director, Procurement Manager, Research Manager | Strong Market Fit, Attendance Not Confirmed |
| The Royal Melbourne Hospital | Hospital / clinical buyer | Key Australian tertiary center for specialist care and research | thermh.org.au | Head of Department, Strategic Sourcing Manager, Clinical Trials Lead | Strong Market Fit, Attendance Not Confirmed |
| Monash Health | Health system buyer | Large network with procurement scale and research programs | monashhealth.org | Procurement Director, Operations Director, Research Partnerships Manager | Strong Market Fit, Attendance Not Confirmed |
| The University of Sydney | Academic / research buyer | Relevant for translational research, clinical studies, and academic sponsorships | sydney.edu.au | Professor, Research Director, Clinical Trials Manager | Strong Market Fit, Attendance Not Confirmed |
| University of Melbourne | Academic / research buyer | Major medical research institution with hepatology and life sciences relevance | unimelb.edu.au | Principal Investigator, Head of Research, Lab Manager | Strong Market Fit, Attendance Not Confirmed |
| NSW Health | Government / procurement organization | Public health network with purchasing influence across the state | health.nsw.gov.au | Contracting Officer, Procurement Manager, Clinical Services Director | Strong Market Fit, Attendance Not Confirmed |
| Australian Red Cross Lifeblood | Health services / diagnostics buyer | Relevant to blood services, diagnostics, clinical research, and healthcare partnerships | lifeblood.com.au | Medical Affairs Lead, Procurement Lead, Research Partnerships Manager | Strong Market Fit, Attendance Not Confirmed |
| Hepatitis Australia | Association / advocacy organization | Aligned with liver disease education, awareness, and policy collaboration | hepatitisaustralia.com | Executive Director, Partnership Director, Programs Manager | Strong Market Fit, Attendance Not Confirmed |
| AbbVie | Pharma buyer / sponsor | Hepatology therapeutic and medical affairs stakeholder | abbvie.com | Medical Affairs Director, Brand Lead, Congress Manager | Strong Market Fit, Attendance Not Confirmed |
| Gilead Sciences | Pharma buyer / sponsor | Relevant to viral hepatitis and liver disease engagement | gilead.com | Medical Science Liaison Lead, Field Medical Director, Events Manager | Strong Market Fit, Attendance Not Confirmed |
| Bristol Myers Squibb | Pharma buyer / sponsor | Potential stakeholder for specialty disease education and medical affairs | bms.com | Medical Affairs Director, Congress Strategy Lead, Partnership Manager | Strong Market Fit, Attendance Not Confirmed |
| Roche | Diagnostics / pharma buyer | Relevant to diagnostics, pathology, and medical affairs | roche.com | Diagnostics Lead, Marketing Manager, Medical Affairs Lead | Strong Market Fit, Attendance Not Confirmed |
| Siemens Healthineers | Medical technology buyer / exhibitor prospect | Relevant to imaging, diagnostics, and hospital technology decisions | siemens-healthineers.com | Product Manager, Business Development Director, Clinical Applications Manager | Strong Market Fit, Attendance Not Confirmed |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Chief Medical Officer / Chief Clinical Officer | Executive / Clinical Leadership | C-level | Influences clinical strategy, adoption, and enterprise vendor decisions |
| 2 | Director of Hepatology / Gastroenterology | Clinical Operations | Director | Primary specialty decision-maker for therapies, diagnostics, and procedure-related tools |
| 3 | Medical Director / Department Head | Clinical Leadership | Director | Influences clinical pathway changes and institutional purchasing recommendations |
| 4 | Procurement Manager / Strategic Sourcing Manager | Procurement / Supply Chain | Manager / Senior Manager | Evaluates suppliers, contracts, and total-cost-of-ownership for healthcare purchases |
| 5 | Clinical Trials Manager / Research Program Manager | Research / Clinical Development | Manager / Senior Manager | Purchases services and solutions supporting studies, sites, and patient recruitment |
| 6 | Medical Science Liaison / Field Medical Director | Medical Affairs | Manager / Director | Drives scientific engagement with KOLs and conference programming |
| 7 | Laboratory Director / Pathology Manager | Laboratory Services | Director / Manager | Important for diagnostic platforms, specimen handling, and workflow tech |
| 8 | Research Director / Principal Investigator | Academia / Research | Senior / Director | Sets research collaborations, grant-funded purchases, and product evaluation standards |
| 9 | Hospital Administrator / Operations Director | Operations / Administration | Director / VP | Influences service delivery, budgets, and vendor onboarding |
| 10 | Congress / Events Manager | Marketing / Events / Sponsorship | Manager / Director | Important for sponsorship, booth, and activation planning by suppliers and pharma brands |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Core attendee and buyer base | Hospital procurement, specialty care, diagnostics, clinical operations |
| 2 | Pharmaceuticals | Therapeutics and medical affairs audience | Drug commercialization, KOL engagement, congress sponsorship |
| 3 | Biotechnology | Research, biomarker, and therapy innovation | Clinical collaboration, translational research, product development |
| 4 | Medical Devices | Procedural and imaging equipment relevance | Device sales, demos, capital equipment, clinical evaluation |
| 5 | Research | Scientific and translational focus | Research services, lab products, data and analytics solutions |
| 6 | Government Administration | Public health and policy stakeholders | Health program procurement, screening, prevention, policy engagement |
| 7 | Biotechnology | Innovation-driven liver disease R&D | Biomarkers, assay platforms, advanced therapeutics |
| 8 | Medical Practice | Specialist clinician base | Physician education, practice tools, referral and diagnostic support |
| 9 | Information Technology & Services | Clinical data, workflow, and digital health solutions | EHR integration, analytics, telehealth, patient engagement |
| 10 | Health, Wellness & Fitness | Prevention, lifestyle, and chronic disease management relevance | Patient support, prevention programs, care pathway solutions |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | More than 2,500 delegates | Confirmed | Official event website | Organizer-provided expectation on current site |
| Exhibitor count | Not publicly confirmed | Unavailable | Official website content reviewed | No exhibitor list provided in the supplied content |
| Buyer count | Not publicly confirmed | Unavailable | Official website content reviewed | Conference is primarily scientific and educational; buying influence is inferred from attendee mix |
| Speaker count | Not publicly confirmed | Unavailable | Official website content reviewed | Program details not supplied in the provided text |
| Sponsor count | Not publicly confirmed | Unavailable | Official website content reviewed | Sponsorship referenced, but no count supplied |
| Historical attendance | Not included | Not used | No verified prior-year attendance figures provided in supplied sources | Current organizer estimate is sufficient for planning |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Clinical education | Updated treatment guidelines, CME, case discussion | Sponsor learning sessions, speaker support, educational grants | Medical education platforms, congress services |
| Diagnostics | Non-invasive testing, biomarkers, pathology workflow | Demonstrate clinical utility and workflow benefits | Lab instruments, assays, imaging solutions |
| Therapeutics | Treatment efficacy, safety, adherence, access | KOL meetings, symposia, medical affairs outreach | Pharma solutions, patient support, real-world evidence |
| Clinical trials | Site access, recruitment, data quality | Target PI networks and research leaders | CRO services, eClinical, patient recruitment tools |
| Hospital procurement | Reliable supply, compliance, value-based purchasing | Procurement meetings, vendor qualification, contract review | Medical devices, consumables, equipment service agreements |
| Research collaboration | Academic-industry partnerships and funding opportunities | Facilitate sponsored research and investigator engagement | Research services, grant support, lab platforms |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | Strong concentration of clinicians, research leaders, pharma, diagnostics, and hospital stakeholders |
| Decision-maker availability | High | Likely access to directors, heads of department, procurement, and medical affairs leaders |
| Data collection potential | Medium | Current attendee list not supplied; however, sponsor, speaker, and society outreach can still support lead building |
| Apollo targeting potential | Very High | Clear title and industry mapping across hospitals, pharma, biotech, research, and government |
| Geographic targeting potential | High | Sydney host city plus strong Asia–Pacific international relevance |
| Best outreach approach | High-touch, scientifically credible, account-based outreach | Use specialty-specific messaging, case studies, and evidence-based value propositions |
| Overall lead quality | Very High | High-value, decision-oriented audience with strong partnership and procurement potential |
| Best use case | Conference lead generation, sponsorship sales, KOL outreach, and healthcare account targeting | Useful for attendee list sales, exhibitor prospecting, and medical-commercial pipeline development |
| Limitations / risks | Moderate | No current attendee list was supplied; actual buyer attendance should be verified against future registration, program, or sponsor materials |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Pharmaceuticals; Biotechnology; Medical Devices; Research; Government Administration; Information Technology & Services | Capture the main attendee and commercial stakeholder groups |
| Departments | Procurement, Supply Chain, Medical Affairs, Clinical Operations, Research, Business Development, Marketing, Events | Align with buying influence and sponsorship decision-making |
| Seniority | Manager, Senior Manager, Director, VP, C-level | Prioritize decision-makers and budget holders |
| Job titles | Procurement Manager, Strategic Sourcing Manager, Medical Director, Head of Hepatology, Clinical Trials Manager, Medical Affairs Director, Research Director, Congress Manager, Director of Partnerships | Directly target likely buyer and influence roles |
| Geography | Australia; New Zealand; Singapore; Japan; South Korea; China; India; Hong Kong; Malaysia; Thailand; Indonesia | Reflect the Asia–Pacific attendee profile and regional buying centers |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Cover specialty clinics through large health systems and multinational sponsors |
| Keywords | hepatology, gastroenterology, liver disease, MAFLD, HBV, HCV, HCC, clinical trials, diagnostics, transplant, pathology, medical affairs, congress | Refine to specialty-specific accounts and programs |
| Company type | Hospital, health system, university, pharma, biotech, medical device, diagnostics, government health agency | Separate end-users from sponsors and strategic partners |
| Technologies | EHR, LIS, clinical trials software, lab automation, imaging systems, analytics, patient engagement | Useful when targeting tech-enabled buyers and solution partners |
| Revenue range | No strict requirement; prioritize mid-market to enterprise for hospital and pharma buying teams | Focus on organizations with active procurement and partnership capacity |
Suggested Apollo Search Logic: (hepatology OR gastroenterology OR liver disease OR MAFLD OR HBV OR HCV OR HCC OR transplant) AND (procurement OR "medical affairs" OR "clinical operations" OR research OR "clinical trials" OR sourcing OR partnerships OR congress) AND (hospital OR pharma OR biotechnology OR "medical devices" OR diagnostics OR university OR government).
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| APASL 2027 Official Website | Official organizer source | Event title, dates, venue, city, country, organizer context, audience estimate, conference themes | Very High |
| Provided official website copy | Primary source text excerpt | Confirmed expected delegate count, program themes, Sydney venue, and organizer messaging | Very High |
| International Convention Centre Sydney | Venue reference | Venue identification in Sydney | High |
| Gastroenterological Society of Australia (GESA) reference in official copy | Association / supporting organization mention | Committee and support context for the Sydney meeting | High |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to APASL - Asian Pacific Association for the Study of the Liver — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds